Health insurer Cigna has issued a positive coverage decision on Uroplasty’s (NSDQ:UPI) overactive bladder (OAB) treatment, Percutaneous Tibial Nerve Stimulation (PTNS).
Uroplasty said the policy will cover PTNS in the treatment of overactive bladder and related symptoms such as urinary urgency, urinary frequency and urge incontinence. The treatment is delivered through Uroplasty’s Urgent PC Neuromodulation System.
The policy took effect Feb. 15 and applies to approximately 14 million Cigna members.
“This positive coverage decision by Cigna brings the total U.S. access to Urgent PC therapy to approximately 123 million lives covered by private payers in addition to over 50 million Medicare beneficiaries,” said Uroplasty CEO Rob Kill, in a release. “This decision further illustrates the medical necessity of PTNS and its value to patients and physicians trying to manage the symptoms of OAB. Urgent PC is a recommended third-line treatment within the OAB treatment guidelines for patients who have not responded or cannot tolerate behavioral intervention and pharmacologic agents.”
In December, Uroplasty announced it planned to merge with Vision-Sciences. Shareholders of both companies are scheduled to vote on the deal March 30.